All Articles

This past year, the COVID-19 pandemic continued to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums. Read More ›

The results of a phase 3, randomized, double-blind study established the equivalence of bevacizumab reference to its biosimilar BCD-021 in terms of clinical efficacy, safety, pharmacokinetics, and immunogenicity in patients with NSCLC. Read More ›

The 5-year follow-up results of a comparative phase 3 study further support the similarity of SB3 and trastuzumab reference with respect to cardiac safety profile and long-term efficacy. Read More ›

The results of the randomized phase 3 TX05-03 study confirmed the therapeutic equivalence of trastuzumab reference and its biosimilar TX05 in terms of pathologic complete response, objective response rate, safety, and immunogenicity. Read More ›

The findings of a survey of US oncologists indicate that practicing oncologists have gaps in their knowledge about biosimilars. Read More ›

A comprehensive, team-based biosimilar adoption model in a community oncology practice demonstrated successful conversion from brand drugs to biosimilars that was associated with substantial cost-savings. Read More ›

Analysis of real-world trends of biosimilar prescribing from 2019 to 2020 indicated rapid uptake of biosimilars among oncology providers, although the extent of biosimilar prescribing varied among products. Read More ›

The findings of a retrospective observational study on healthcare resource utilization and cost patterns after formulary conversion to a biosimilar indicate that overall results may be driven by behavior at initial formulary switch. Read More ›

Real-world evidence indicates robust biosimilar uptake of the first FDA-approved bevacizumab biosimilar, bevacizumab-awwb, across its approved indications, including metastatic colorectal cancer and non–small-cell lung cancer. Read More ›

The findings from a small, retrospective study suggest that same-day pegfilgrastim-cbqv was a safe and effective alternative to standard administration 24 hours postchemotherapy for the primary and secondary prophylaxis of febrile neutropenia with myelosuppressive chemotherapy in patients with breast cancer. Read More ›